"Over the past five years, Teva has been transformed from a successful generics business into a major global pharmaceutical company. We have achieved double-digit increases in sales and earnings, and have built, acquired or partnered to create new opportunities to support future sustainable growth," Shlomo Yanai, outgoing CEO, Teva, 2012

Teva is a global pharmaceutical company established in Jerusalem in 1901 and specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients.

Highlights

• With operations in over 60 countries and approximately 46,000 employees worldwide, Teva Pharmaceuticals offers the widest range of cost-effective pharmaceuticals, both generic and branded, to millions of consumers, customers and healthcare providers.

• Teva is among the top 15 pharmaceutical companies in the world and the largest generic pharmaceutical manufacturer in the world.

• Teva has production facilities in Israel, North America and Latin America and Europe, and operates through a carefully tailored network of worldwide subsidiaries.

• Teva markets and develops innovative drugs for specialized markets and produces generic drugs in all major therapeutic categories.

• The pharmaceuticals division is responsible for 90% of Teva’s revenues.

• Teva owns the exclusive license to develop the drug, Copaxoane, (glatiramer acetate) for the treatment of multiple sclerosis which is marketed and sold in 47 countries.

• 2012 -Teva begins trading on the New York Stock Exchange (NYSE).

• Also in 2012, Dr. Jeremy Levin, a former senior executive at Bristol-Myers Squibb (NYSE:BMY), succeeds Shlomo Yanai as CEO.

Products and Acquisitions
 
2011: Teva acquires large US company Cephalon, and Taiyo, the third largest pharmaceutical company in Japan.

2010: Teva acquires Germany's Ratiopharm, turning Teva into the leading generic pharmaceutical company in Europe.

2008: Teva acquires Barr Pharmaceuticals.
USFDA grants final approval for generic Fosomax tablets.
USFDA grants tentative approval for generic Flomax and Prevaid delayed action capsules.
Teva acquires CoGenesys, a privately held biopharmaceutical company.

2007: USFDA approves generic Dostine and Alprazola tablets.

2006: Teva launches sales of Zoloft and generic Wellbutrin tablets.
Teva acquires IVAX Corporation.

2004: Teva completes the acquisition of US company Sicor, for $3.4 billion, representing the largest-ever such acquisition by an Israeli company to date. 
 
Returns

• Net income for 2007 reached $1.952 billion (+5% over 2006).
• Net sales for 2007 were $9.4 billion.
• $18.3 billion annual sales in 2011

*Pictures courtesy of Teva